Tag Archive for: ODD

Gate2Brain obtains FDA Orphan Drug Designation for G2B-002

, ,
US FDA grants Orphan Drug Designation for G2B-002 in 2025, underscoring U.S. regulatory support for…

Gate2Brain and its “molecular tractors” technology: new way to optimize the transport of drugs to the brain

,
Article by Andrea Rivero García Meritxell Teixidó, CEO and co-founder of Gate2Brain, explains in an…

Gate2Brain Receives EMA Orphan Drug Designation for Its Groundbreaking G2B-002

, ,
PRESS RELEASE Barcelona, November 2024 – Gate2Brain, a cutting-edge technology platform focused on…
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social